论文部分内容阅读
目的探讨胆汁ＣＡ１９－９在胆道良恶性病变的诊断价值。方法本研究选择经手术及病理证实的胆道恶性肿瘤２６例，胆道良性病变９２例，正常健康人１３例，采用ＲＩＡ同时联合检测胆汁ＣＡ１９－９、ＣＥＡ，进行定量分析。结果胆汁ＣＡ１９－９的含量分界值为１２０００ｕ／ｍｌ，其敏感性，特异性分别为９２．３１％，７２．８３％；胆汁ＣＥＡ水平分界值为４９０ｎｇ／ｍｌ，其相应指标分别为５７．６９％、７８．２６％。胆汁ＣＡ１９－９、ＣＥＡ含量的假阳性率分别为２７．１７％、２１．７３％。结论胆汁ＣＡ１９－９是诊断胆道癌，判断胆道癌是否被彻底切除，以及监测该病治疗反应有效的肿瘤标志物。
Objective To investigate the diagnostic value of bile CA19-9 in benign and malignant bile duct lesions. METHODS: Twenty-six cases of biliary malignancies confirmed by surgery and pathology, 92 cases of benign biliary lesions and 13 cases of normal healthy subjects were selected in this study. Biliary CA19-9 and CEA were simultaneously analyzed by RIA for quantitative analysis. Results The cut-off value of bile CA19-9 was 12000 u/ml, its sensitivity and specificity were 92.31% and 72.83%, respectively. The cut-off value of bile CEA was 490 ng/ml, and the corresponding indexes were 57.69 respectively. %, 78.26%. The false positive rates of bile CA19-9 and CEA were 27.17% and 21.73%, respectively. [Conclusion] Bile CA19-9 is a tumor marker for diagnosing biliary tract cancer, judging whether biliary tract cancer has been completely resected, and monitoring the treatment response of the disease.